Oncoral in short
Oncoral is novel patented irinotecan chemotherapy tablet. With daily dosing, Oncoral has the potential to offer both efficacy and safety benefits to cancer patients compared to intravenous high-dose infusions at the hospital
Development plan – Phase 2 and onwards
The development plan is to conduct a Phase 2 study in gastric cancer and from there potential label expansion into other solid cancer indications.
Strategic plans for Oncoral and its potential role in as a novel chemotherapy tablet helping patients suffering from cancer
Presentation of the unmet medical need to be filled by Oncoral as well as the clinical development plan
Oncology expert Prof. Jeff Evans talks about the great unmet need to develop novel drugs for the treatment of gastric cancer. Jeff Evans forms part of Ascelia Pharma's Scientific Advisory Board for Oncoral.